Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No More Ouch! Vaccine Delivery is Changing

This article was originally published in Start Up

Executive Summary

Since the mid-1950's getting "shots" has been a source of childhood terror. Now, small companies are looking at ways to deliver vaccines through the oral or nasal mucosa, or using needle-free skin delivery systems to take advantage of immune cells within the skin.

You may also be interested in...



Oxagen Ltd.

Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.

polyGenomics Inc.

PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.

Genome Pharmaceuticals

Genome Pharmaceuticals of Germany is a full-service genomics company that claims "one-top shopping" for target identification.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel